Rocchio Megan A, Schurr James W, Hussey Aaron P, Szumita Paul M
1 Brigham and Women's Hospital, Boston, MA, USA.
Ann Pharmacother. 2017 Feb;51(2):135-139. doi: 10.1177/1060028016673071. Epub 2016 Oct 6.
In October 2010, a pharmacist-driven stewardship program was implemented at the Brigham and Women's Hospital to ensure continued adherence to the prescribing guideline, focusing on indications for intravenous immune globulin (IVIG) use and dosing per ideal body weight.
The primary objective was to describe an IVIG stewardship program at a tertiary academic medical center.
This was a prospective, observational study from January 2013 through December 2014. All patients ordered to receive IVIG during the defined study period were included. The intervention assessed describes a pharmacist-driven IVIG stewardship program for medication approval. The primary end point was guideline compliance based on indication, dose, dosing weight, and frequency. Secondary end points included the number of patients receiving IVIG, indications, orders discontinued as a result of guideline nonadherence, and total amount dispensed.
A total of 418 patients were identified during the study time frame. The top indications were: hypogammaglobulinemia in bone marrow transplantation and hematological malignancy (50.7%), acute solid organ rejection (11.8%), and immune thrombocytopenia with bleeding (10.1%). In all, 12 patients (2.9%) received IVIG for an indication nonadherent with the IVIG prescribing guideline; 9 patients (2.2%) and 2 patients (0.5%), respectively, received a different dose or frequency per the prescribed indication; and 12 orders (2.9%) for indications nonadherent to the guideline were discontinued. A total of 26 033 g of IVIG were dispensed during the study period.
An IVIG stewardship program, including an institution-specific prescribing guideline and a pharmacist-driven stewardship program, may ensure guideline compliance for appropriateness of indication and dose at an academic medical center.
2010年10月,布莱根妇女医院实施了一项由药剂师主导的管理项目,以确保持续遵循处方指南,重点关注静脉注射免疫球蛋白(IVIG)的使用指征及基于理想体重的给药剂量。
主要目的是描述一家三级学术医疗中心的IVIG管理项目。
这是一项从2013年1月至2014年12月的前瞻性观察性研究。纳入了在规定研究期间所有医嘱使用IVIG的患者。所评估的干预措施描述了一项由药剂师主导的用于药物审批的IVIG管理项目。主要终点是基于指征、剂量、给药体重和频率的指南依从性。次要终点包括接受IVIG的患者数量、指征、因未遵循指南而停用的医嘱以及总配药量。
在研究时间段内共识别出418例患者。最常见的指征为:骨髓移植和血液系统恶性肿瘤中的低丙种球蛋白血症(50.7%)、急性实体器官排斥(11.8%)以及伴有出血的免疫性血小板减少症(10.1%)。共有12例患者(2.9%)因使用IVIG的指征不符合IVIG处方指南而接受了IVIG治疗;分别有9例患者(2.2%)和2例患者(0.5%)根据规定指征接受了不同的剂量或频率;12份不符合指南指征的医嘱(2.9%)被停用。在研究期间共配发了26033克IVIG。
一个IVIG管理项目,包括机构特定的处方指南和由药剂师主导的管理项目,可能确保学术医疗中心在指征和剂量适宜性方面遵循指南。